Reports_Coming_Soon_Page_Header_Set_Up_Desktop_new-min

Future MyOme Reports
and Genetic Tests

Learn more about the genetic tests and reports that are coming soon or are in development for the MyOme Personal Genome platform. MyOme Personal Genome unlocks a lifetime of health information from only one sample submission, and our MyOme Genetic Tests cover a range of clinical conditions*.

Coming Soon to the MyOme Platform

MyOme Personal Genome Risk Reports

Coronary Artery Disease (CAD) Integrated Risk with Personal Risk Score (PRS) Report

CAD is the most common type of heart disease in the U.S., impacting people of all ages, with 2 in 10 deaths from CAD occurring in adults under 65.1 We’re developing this report so everyone can check their heart health anytime.
About the Report

The report provides a single risk score that integrates genetics with clinical factors to assess risk for coronary artery disease (CAD) for those who may be missed by clinical evaluation (whereas traditional genetic panels evaluate rare genes impacting a small percent and do not assess CAD risk).

Breast Cancer Integrated Risk with Personal Risk Score (PRS) Report

 

Nearly 1 in 8 women in the U.S. will develop invasive breast cancer throughout their lives.2 We’re developing this report to offer women on-demand access to their breast cancer risk at any age. See our publication on breast cancer risk stratification.

About the Report
If you have a family history of breast cancer but are negative for single-gene tests, including BRCA1 or BRCA2, you can still be at an elevated risk for breast cancer. 3 This report provides an integrated risk score that combines genetics with clinical risk factors for women without a known mutation in a breast cancer gene.4 This test is validated across multiple ancestries.5

MyOme Genetic Tests

Neurodevelopmental Delay (NDD) Genetic Test

Despite current testing guideline recommendations for NDD, 2 out of 3 children do not receive genetic testing. 5 Current testing is complex and expensive, often leaving families without a clear diagnosis. Our test offers a comprehensive genetic testing option that streamlines the path ahead for families.
About the Report
If you believe your child has a developmental delay, this test provides an affordable genetic test option that utilizes MyOme whole genome sequencing. The test detects a wide range of changes in the genome, known as variants, which may cause developmental delay. This includes single nucleotide variants and copy number variants from as small as 10kb to single genes. Test results are delivered in weeks and may improve access to additional advanced tests if necessary.

Reports in Development

MyOme Personal Genome Risk Reports

1. National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER Database. Accessed September 13, 2023.
2. Breast Cancer Facts and Statistics 2023, www.breastcancer.org/facts-statistics. Accessed 13 Sept. 2023.
3. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015 Jul;26(7):1291-9. doi: 10.1093/annonc/mdv022. Epub 2015 Jan 20. PMID: 25605744; PMCID: PMC4478970.
4. Tshiaba, P., et al. Improved Breast Cancer Risk Stratification by Integration of a Cross-ancestry Polygenic Model with Clinical Risk Factors # PB3447 Presented at the Annual Meeting of The American Society of Human Genetics, October 27, 2022, Los Angeles
5. Savatt Juliann M. et al, Frontiers in Pediatrics V92021
* In some cases an additional sample might be required.  

Contact Us

We are happy to answer any questions. Contact us at with any questions or to keep apprised of any development, provide your name and email information.

OFFICE and LAB: Menlo Park, California 

Linkedin
© 2023 MyOme.com
MyOme is not responsible for the content or accuracy of third-party websites
The MyOme Personal Genome Report was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary for laboratory-developed tests.